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Clinical trials are important for clinical practice; therefore, it is 
essential that the findings of such studies are trustworthy. 
Different types of bias can interfere with the results of indi-
vidual studies assessing therapeutic interventions by distorting 
the direction and size of the effect estimates (Savovic et al. 
2018). Common types of bias in clinical trials include selec-
tion, performance, detection, attrition, and reporting bias and 
are associated with improper methodology applied during the 
design, conduct, analysis, and reporting of the trial (Persaud 
and Heneghan 2021). Such biases can hamper trial internal 
validity, render study results invalid, and compromise health 
care recommendations and patient care.
It is advocated that health care recommendations should be 
based on the totality of the available high-quality evidence via 
synthesis commonly found in the form of systematic reviews 
with meta-analysis. An issue acting against this principle is 
publication bias (Dickersin 1990), which refers to the publica-
tion or not of trial findings based on the size and direction of 
the observed treatment effects, a persistent problem despite the 
increased awareness (Fanelli 2012). In the context of academic 
success and under the “publish or perish” principle, research-
ers have strong incentives to publish their results quickly, fur-
ther contributing to publication bias and false discovery rates 
(Simmons et al. 2011). Suspicion of publication bias can result 
in questionable meta-analysis estimates, as the gathering of the 
totality of the evidence is precluded since some studies with 
smaller treatment effects may not be published, thus biasing 
meta-analysis estimates away from the null.
There is great enthusiasm in discovery of new treatments 
that are expected to improve patient care; however, there is 
evidence in the literature that strong treatment effects in early 
and especially small trials can be refuted in consequent trials 
(Simmons et al. 2011). Such bias where initially strong treat-
ment effects are not confirmed in subsequent studies has been 
coined “novelty bias” and may be the result of a combination 
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Abstract
Differences in effect estimates between early primary trials included in a meta-analysis and the pooled estimate of meta-analysis might 
indicate potential novelty bias. The objective of this study was to assess the presence of novelty bias in a sample of studies published 
in periodontology and implant dentistry. On August 7, 2020, we searched the PubMed database for meta-analyses of clinical studies 
published between August 2015 and August 2020. Meta-analyses with at least 4 primary studies were selected for assessment. We 
fitted logistic regression models using trial characteristics as predictors to assess the association between these characteristics and 1) 
the odds of the first trial’s estimate to be included in the meta-analysis confidence interval (CI) and 2) the odds of overlap between the 
first trial’s CI and the meta-analysis prediction interval (PI). Ninety-two meta-analyses provided data for assessment. In absolute values, 
70% of the meta-analyses have a pooled estimate smaller than the corresponding estimate of the first trial, although there was overlap 
of the CI of estimates from the first trial and the meta-analysis in 87% of the cases. This is probably due to the small number of trials 
in most meta-analyses and the subsequently large uncertainty associated with the pooled effect estimate. As the number of trials in the 
meta-analysis increased, the odds of the treatment effect estimate of the first trial to be included in the meta-analysis CI decreased by 
15% for every additional trial (odds ratio, 0.85; 95% CI, 0.73 to 0.96). Meta-analytic effect estimates appear to be more conservative 
than those from the first trial in the meta-analysis. Our findings show evidence of novelty bias in periodontology and implant dentistry; 
therefore, clinicians should be aware of the risk of making decisions based on the information reported in new trials because of the risk 
of exaggerated estimates in these trials.
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of biases observed during the design, conduct, analysis, and 
reporting of a trial (Ioannidis 2008; Persaud and Heneghan 
2021). As it is common for meta-analyses to have few studies, 
the possibility of early trials with exaggerated results is likely 
to inflate the pooled effect. Novelty bias, which implies that 
results of early trials can be exaggerated, can pose a problem in 
patient care if clinicians incorporate interventions based solely 
on the results of early trial results. Therefore, clinicians should 
be cautious into adopting new treatments based on limited 
data.
Ioannidis (2005) examined such controversies in 49 highly 
cited studies (>1,000 citations) published in 3 major general 
clinical journals or high–impact factor specialty journals 
between 1990 and 2003 covering a range of medical interven-
tions. Among the 49 first trials, 45 concluded that the interven-
tion was effective. The results of 7 of 45 (16%) were 
contradicted by subsequent studies; in another 7 of 45 (16%), 
the effects of the first trial were stronger than those of subse-
quent studies; 20 of 45 (44%) were replicated; and 11 of 45 
(24%) remained largely unchallenged. Novelty bias has been 
also identified for some lipid-lowering antiglaucoma drugs 
(Gehr et al. 2006), cancer treatment (Salanti et al. 2010), 
interferon hepatitis C treatments (Tinè et al. 2017), and antide-
pressants (Cipriani et al. 2018). Using cumulative network 
meta-analysis, Luo et al. (2021) indicated initially stronger 
effects for antidepressants, which stabilized, however, and the 
confidence in the evidence increased with the addition of new 
studies over time.
A relevant problem is the reproducibility of study findings, 
as recently highlighted in the field of psychology where repro-
ducibility after replication of initial studies was relatively low 
(Open Science Collaboration 2015). In 100 studies, replication 
effects were half the magnitude of first study effects. In 98% 
of the first studies, the results were statistically significant, 
whereas 36% of replications had statistically significant results; 
47% of first effect sizes were included in the 95% confidence 
interval (CI) of the replication effect size. In 39% of the repli-
cated studies, the first study effects were subjectively rated to 
have replicated the original result.
Systematic assessment of novelty bias in the field of den-
tistry is very limited, with 1 study assessing temporal trends in 
the efficacy of periodontal regeneration where no temporal 
trends were identified (Tu et al. 2008). Therefore, the aim of 
this meta-epidemiologic study, as the evidence accumulates, 
was to examine whether there is evidence of novelty bias in 




We included meta-analyses of clinical studies on different 
types of therapeutic interventions related to periodontology 
and implant dentistry. Systematic reviews not involving 
humans and meta-analyses involving the association of risk 
factors and periodontal and dental implant outcomes were 
excluded. Meta-analyses other than pairwise were excluded. 
We defined different thematic areas in periodontology and 
implant dentistry to guide our systematic approach for select-
ing studies.
Periodontology
1) Local and systemic antibiotics for periodontal treatment
2) Regeneration procedures for infrabony defects (e.g., 
enamel matrix derivative, guided tissue regeneration, 
bone substitutes without membrane)
3) Periodontal plastic surgery (e.g., gingival recession proce-
dures, soft tissue augmentation for the alveolar ridge)
Implant Dentistry
1) Nonsurgical treatment for mucositis and peri-implantitis
2) Surgical treatment for peri-implantitis
3) Different types (length/diameter) and surfaces of dental 
implants (e.g., survival of implant surface, treatment of 
peri-implant problems in surfaces)
4) Any kind of guided bone regeneration (e.g., external and 
internal sinus lift, vertical augmentation, site preservation)
Meta-analyses published in English containing at least 4 
clinical trials were included. The minimum number of 4 trials 
was considered necessary for any trends over time to be 
detected.
Search and Selection of Meta-analyses
In the PubMed database, we searched meta-analyses published 
between August 2015 and August 2020 by using specific key-
words directly related to the thematic areas. We limited our 
search to more recent systematic reviews to allow a better com-
parison between the oldest trials and the meta-analysis pooled 
estimate. More recent reviews are more likely to include a 
larger number of trials in the meta-analyses. The search pro-
cess was conducted independently and in duplicate by 2 
authors (M.C.M., C.M.F.). For the detailed search strategy, see 
Appendix Table 1.
We selected the forest plots directly related to the primary 
outcomes of at least 4 trials. In case of no report of primary 
outcomes, we selected the forest plots with the greatest number 
of primary studies. If multiple selected forest plots had the 
same number of studies, we included all of them.
Two authors (M.C.M., C.M.F.) selected a sample of eligible 
studies and achieved good agreement (at least 80%), with the 
remainder selected by 1 reviewer (M.C.M.) (Shea et al. 2017).
Data Extraction
We extracted the following information from the systematic 
reviews and meta-analyses: publication year, type of meta-
analysis (Cochrane vs. non-Cochrane), type of trial (RCT and 
non-RCT, including design), continent of the first author, den-
tal specialty (periodontology or implant dentistry), thematic 
area, journal impact factor, risk of bias (RoB) of primary stud-
ies (median, interquartile range [IQR]), type of outcome 
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(binary, continuous), and type of synthesis (fixed or random 
effects). Two authors (M.C.M., C.M.F.) extracted data from a 
sample of eligible studies and achieved good agreement (at 
least 80%), with the remainder extracted by 1 reviewer 
(M.C.M.) (Shea et al. 2017).
Data Analysis
We focused on meta-analyses that contain at least 4 trials and 
have a publication time span of at least 4 y, with the effect size 
measured as either a mean difference or a standardized mean 
difference. For standardization purposes and especially because 
the number of binary outcomes was limited, we analyzed con-
tinuous outcomes only. Statistically or clinically significant dif-
ferences (as implied from the confidence and prediction 
intervals) between the first trial’s effect estimate and the meta-
analysis pooled estimate are assumed to be a sign of novelty 
bias. Since reporting of PIs was rare, we calculated them by 
re-running all the included meta-analyses with the option to 
include PIs. To demonstrate this, we explored visually and sta-
tistically via logistic regression models if these differences are 
associated with various meta-analysis characteristics, such as 
the range of publication years, the number of trials, and the RoB 
(RoB of the first trial worse than the average RoB). We fitted 2 
logistic regression models using the aforementioned trial char-
acteristics as predictors to examine if there is an association 
between these characteristics and the odds of 1) the first trial’s 
estimate to be included in meta-analysis CI and 2) an overlap 
between the first trial’s CI and meta-analysis prediction interval 
(PI). The outcome in both scenarios is binary—such as overlap 
(no novelty bias suspected) and no overlap (novelty bias sus-
pected)—between early estimates and pooled estimates CIs or 
overlap between the first trial’s CI and meta-analysis PI. The 
odds ratio (OR) is the effect measure used when fitting a logis-
tic model, and higher odds with small P values would provide 
evidence against the null hypothesis. The PI shows the range of 
plausible values for future trials (Riley et al. 2011). In all analy-
ses, we used a significance level of 5%. We used Wald’s statistic 
to test the significance of predictors. All analyses were con-




The search initially retrieved 282 potential documents, and 94 
systematic reviews were included, comprising 349 meta- 
analyses for potential assessment. Figure 1 presents the search and 
selection process. The full lists of included and excluded stud-
ies, with reasons for exclusion, are reported in the Appendix. 
Of the 349 meta-analyses fulfilling the initial eligibility crite-
ria, 92 meta-analyses satisfied our inclusion criteria for novelty 
bias assessment. From the 94 systematic reviews, just 2 were 
Cochrane reviews, and the greatest proportion (n = 56, 60%) 
were published in the field of implant dentistry. Periodontal 
plastic surgery was the most prevalent topic (n = 28, 30%), and 
most systematic reviews were published in 2018 (n = 31, 33%). 
The first author of most systematic reviews (n = 34, 36%) was 
based in Europe, and the Journal of Clinical Periodontology 
had the greatest number (n = 10, 11%) of systematic reviews 
published. For systematic review characteristics, see Appendix 
Table 2. The meta-analyses had a median publication span of 
8 y (IQR, 6 to 11; mean, 8.79; range, 4 to 22) and a median 6 
studies (IQR, 5 to 9.25; mean, 7.61; range, 4 to 27).
The median sample size for the first trial was 30 (IQR, 23 to 
44; mean, 41.98; range, 14 to 134). The median sample size for 
the pooled estimate was 282 (IQR, 197 to 469; mean, 369.86; 
range, 88 to 2,281).
Data Analysis
Table 1 shows an overlap between the 95% CI of the first trial 
and 1) that of the meta-analysis pooled effect in 87% of the 
cases and 2) the 95% PI in 99% of the cases. In 58% of our 
meta-analyses, there was a significant pooled estimate, and in 
70% the pooled estimate was smaller than the corresponding 
estimate of the first trial (in absolute values). The first trial’s 
estimate was included in meta-analysis confidence and predic-
tion intervals at 52% and 92% of the cases, respectively.
Differences in trial characteristics among the cases are pre-
sented in Figure 2. From the figure, we observe that the num-
ber of studies is higher when the meta-analysis treatment 
estimate is significant. Significant differences were not found 
for the range of the publication years and the ratio between the range 
of the meta-analysis CI and the range of the first trial’s CI.
Figure 1. Flowchart of article selection.
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We computed Wald’s z values (effect over the standard 
error) for the effect size of the first trial and for the pooled 
effect. The density plot (Fig. 3) indicates that Wald’s absolute z 
values <1.96 are almost equally likely to be observed in the 
meta-analysis and the first trial. It should be noted that in the 
range between 0 and 5, it seems that the 2 distributions do not 
significantly differ.
We tested statistically whether the odds that the treatment 
effect estimates of the first trial to be included in the meta-analysis 
CI are associated with various meta-analysis characteristics 
Table 1. Observed and Expected (95% CI) Frequency of Different Cases.
% (95% CI)
 Yes No
Overlap between meta-analysis  
 Confidence interval and first trial’s confidence interval 87 (80 to 94) 13 (6 to 20)
 Prediction interval and first trial’s confidence interval 99 (97 to 100)  1 (0 to 3)
Meta-analysis treatment estimates statistically significant 58 (48 to 68) 42 (32 to 52)
First trial’s  
 Treatment estimate included in meta-analysis confidence interval 52 (42 to 62) 48 (38 to 58)
 Absolute treatment estimate larger than meta-analysis absolute treatment estimate 70 (60 to 79) 30 (21 to 40)
 Treatment estimate included in meta-analysis prediction interval 92 (87 to 98)  8 (2 to 13)
Figure 2. Box plots for the number of trials, the range of publication years, and the ratio between the range of the meta-analysis CI and the first 
trial’s CI, showing treatment effects when the first trial’s estimates fulfill (YES) or not (NO) the following criteria: (a) the CI overlaps with the meta-
analysis CI, (b) the CI overlaps with the meta-analysis PI, (c) a statistically significant treatment estimate both in the first trial and meta-analysis results, 
(d) the treatment estimate is included in the meta-analysis CI, (e) the treatment estimate has a larger absolute value than the corresponding meta-
analysis treatment estimate, and (f) the treatment estimate is included in the meta-analysis PI. Values are presented as limits of the box plot (line), 
interquartile range (box), and exaggerated effect estimates outside box plot limits (circles).
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and trial characteristics by applying a logistic 
regression model. We found that year of publication 
(OR, 1.06; 95% CI, 0.95 to 1.20) and RoB (OR, 
1.50; 95% CI, 0.63 to 3.69) do not significantly 
affect these odds, but the odds of the 95% CI of the 
first trial’s effect overlapping the pooled 95% CI 
increases by 50% if the first study is at high RoB. 
The number of trials significantly influence the 
odds by reducing them 15% per 1 extra study in the 
meta-analysis (OR, 0.85; 95% CI, 0.73 to 0.96). The 
odds of observing an overlap between the first trial’s 
CI and the meta-analysis PI are significantly 
affected from only the number of trials, reducing the 
odds by 22% per extra study in the meta-analysis 
(OR, 0.78; 95% CI, 0.63 to 0.97; Table 2). It is likely 
that in most meta-analyses, we lack power to find 
significant differences between the effect estimate 
of the first trials and the meta-analysis pooled effect 
estimate. We found a median 6 studies, with 75% of 
the meta-analyses including up to 9 studies. In meta-analysis 
with a relatively large number of studies, novelty bias patterns 
are more evident. In both analyses, there was much uncertainty 
associated with the RoB.
Discussion
The aim of this study was to assess the presence of novelty bias 
in periodontics and implant dentistry. We used as measures of 
novelty bias differences in the effect size between pooled 
meta-analysis treatment effects and first trial treatment effects 
as well as the degree of overlap in uncertainty measures, such 
as 95% confidence and prediction intervals. The PI—which is, 
unfortunately, not often used (Chiolero et al. 2012)—is a good 
indicator of the range of the treatment effect estimate of a 
future trial (Riley et al. 2011). The present findings suggest the 
possibility of novelty bias in the selected sample when com-
paring the first trial’s absolute treatment estimate and that of 
the meta-analysis pooled estimate. However, novelty bias 
seems to be fading when the basis of the assessment is the 
wider PI. Regression analyses indicated that among year of 
publication, RoB, and number of trials in the meta-analyses, 
only the last reached statistical significance.
Previous studies have reported signs of novelty bias (Barbui 
et al. 2004; Gehr et al. 2006; Salanti et al. 2010; Tinè et al. 
2017; Cipriani et al. 2018). Salanti et al. (2010) identified nov-
elty bias in cancer treatment using a meta-regression model. 
Similar patterns were observed for antidepressants (Cipriani 
et al. 2018) and for some lipid-lowering antiglaucoma drugs 
(Gehr et al. 2006). This tendency was confirmed in the present 
study where meta-analytic estimates were more conservative 
in absolute values; however, when the comparison moved from 
estimates to overlapping confidence and prediction intervals, 
novelty bias seemed to be waning. As the number of trials 
increased, the odds of nonoverlapping estimates and their 
range between the first study and the meta-analytic pooled esti-
mate decrease, suggesting the presence of novelty bias. It is 
also reasonable to assume that as the number of studies 
increases, the estimates are more stable and that the confidence 
in the results increases.
In our sample, meta-analyses where the first trial treatment 
effects were not in the meta-analysis PI were identified in 
regeneration of periodontal tissues. For example, 2 meta-anal-
yses focused on the treatment effect of the use of platelet con-
centrates as adjunctive for the treatment of gingival recessions 
(Li et al. 2019) and furcation defects (Panda et al. 2019). In the 
Figure 3. Density plot of the absolute z values of the Wald statistic between the 
first trial and the meta-analysis. The dotted line indicates the absolute z value with an 
equal likelihood of being observed in the meta-analysis and the first trial.
Table 2. Logistic Regression Coefficients.
Predictor Odds Ratio (95% CI) P Value
Observe a treatment estimate of the first trial to be included in meta-analysis confidence interval
Range of publication years 1.06 (0.95 to 1.20) 0.31
No. of trials 0.85 (0.73 to 0.96) 0.02
Risk of bias 1.50 (0.63 to 3.69) 0.37
Hosmer-Lemeshow goodness-of-fit test: χ2 = 11.25, df = 8, P = 0.19
Observing an overlap between the first trial’s confidence interval and meta-analysis prediction intervala
Range of publication years 0.85 (0.61 to 1.19) 0.34
No. of trials 0.78 (0.63 to 0.97) 0.03
Risk of bias 1.07 (0.04 to 27.34) 0.97
Hosmer-Lemeshow goodness of fit test: χ2 = 1.13, df = 8, P > 0.99
aEstimates from penalized logistic regression.
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first case, the estimate of the first trial in the meta-analysis was 
−0.20, and the PI of the meta-analysis ranged from −0.18 to 
0.74. In the meta-analysis on the treatment of furcation defects, 
the estimate of the first trial was 2.40, and the PI of the respec-
tive meta-analysis ranged from 0.56 to 2.11. Furthermore, 1 
meta-analysis (da Rosa et al. 2018) assessed the efficacy of 
bioactive proteins for bone regeneration in implant-based reha-
bilitation. In this case, the first trial reported an estimate of 
–0.74 with the PI of the corresponding meta-analysis ranging 
from –0.61 to 0.07. The mechanism that may explain novelty 
bias is not fully clear. Novelty bias might be connected to 
vibrational effects due to flexible analyses and other types of 
bias, such as selective outcome reporting (Ioannidis 2008) and 
selection bias (Persaud and Heneghan 2021), when patients are 
selected on the basis of a favorable response to the proposed 
new therapy. Initial enthusiasm is not the only reason that we 
may observe a difference between first trial’s effect estimate 
and the pooled effect estimate. Other potential reasons include 
publication bias, RoB, and improvements in methodology. In 
our sample, the median publication time span is 8 y with most 
meta-analysis having a range <10 y. In such a relatively small 
time span, the impact of the aforementioned features on the 
difference between the first trial’s effect estimate and the 
pooled effect estimate may be limited. However, this is likely 
to be related with the type of intervention and the clinical 
research activity in the area. In addition, the number of trials in 
the meta-analyses is relatively small, suggesting in general low 
power in detecting novelty effects when the first trial estimate 
is compared with the PI.
Bias in trials is hard to quantify; however, there is empirical 
evidence suggesting measures that reduce bias in trials (Schulz 
et al. 1995; Savović et al. 2012; Savovic et al. 2018), such as 
randomization with allocation concealment and blinding, 
where feasible. It is not fully clear how novelty bias arises, but 
it has been suggested that it may be the result of a combination 
of biases observed during the design, conduct, analysis, and 
reporting of a trial (Ioannidis 2008; Persaud and Heneghan 
2021). Therefore, abiding to solid trial methodology principles 
across all trial stages is expected on average to reduce novelty 
bias. Novelty bias is more likely when the evidence is limited 
and during the early period of introducing a new intervention. 
At those stages, the possibility of a false-positive result and/or 
publication based on the size and direction of the effect (publi-
cation bias) should not be ignored. From a practical perspec-
tive, clinicians should be aware to not easily adopt new 
treatment modalities with limited evidence.
Strengths and Limitations
To our knowledge, this is one of the first studies in dentistry to 
address the topic of novelty bias. Although many meta-analyses 
likely lack power due to the limited number of trials, there was 
a substantial number of meta-analyses that allowed the analy-
sis in various periodontology and implant dentistry topics. The 
use of prediction intervals is a new approach in assessing nov-
elty bias, as it accounts for the uncertainty in the estimate of a 
future trial; this approach makes the results of this study more 
robust. Limitations of the study include reduced generalizabil-
ity of our findings to other dental fields and the potential of 
selection bias, as only the meta-analyses published in English 
were selected. In addition, the endemic problem of the limited 
number of trials, which are usually small, and the relatively 
short range of publication years contribute to the uncertainty of 
the results. We also searched in only 1 major database, and 
some studies that could be important for comparisons may 
have been excluded. Nevertheless, we feel that a good number 
of meta-analyses were included that well represent the chosen 
field.
Conclusion
The present findings suggest that there is some evidence of 
novelty bias in meta-analyses published in periodontology and 
implant dentistry. However, the often-limited number of trials 
across the various topics restricts the ability to fully assess nov-
elty bias. Nevertheless, consumers of research should be aware 
that initially optimistic treatment effects may be influenced by 
novelty bias and can be refuted in future trials.
Author Contributions
M.C. Menne, contributed to data acquisition, contributed to inter-
pretation of the manuscript and critically revised the manuscript; 
G. Seitidis, contributed to the statistical analyses and interpreta-
tion, critically revised the manuscript; C.M. Faggion Jr, contrib-
uted to design, data acquisition, and interpretation, first drafted 
and critically revised the manuscript; D. Mavridis, contributed to 
design, statistical analyses, and interpretation, critically revised 
the manuscript; N. Pandis, contributed to conception, design, sta-
tistical analyses and interpretation, drafted and critically revised 
the manuscript. All authors gave final approval and agree to be 
accountable for all aspects of the work.
Declaration of Conflicting Interests
The authors declared no potential conflicts of interest with respect 
to the research, authorship, and/or publication of this article.
Funding
The authors received no financial support for the research, author-
ship, and/or publication of this article.
ORCID iDs
M.C. Menne  https://orcid.org/0000-0002-9175-0688
G. Seitidis  https://orcid.org/0000-0003-0856-1892
C.M. Faggion Jr  https://orcid.org/0000-0001-8323-909X
References
Barbui C, Cipriani A, Brambilla P, Hotopf M. 2004. “Wish bias” in antidepres-
sant drug trials? J Clin Psychopharmacol. 24(2):126–130.
Chiolero A, Santschi V, Burnand B, Platt RW, Paradis G. 2012. Meta-
analyses: with confidence or prediction intervals? Eur J Epidemiol. 
27(10):823–825.
Early Optimistic Effect in Periodontology 7
Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, 
Leucht S, Ruhe HG, Turner EH, Higgins JPT, et al. 2018. Comparative 
efficacy and acceptability of 21 antidepressant drugs for the acute treatment 
of adults with major depressive disorder: a systematic review and network 
meta-analysis. Lancet. 391(10128):1357–1366.
da Rosa WLO, da Silva TM, da Silva AF, Piva E. 2018. Bioactive treatments in 
bone grafts for implant-based rehabilitation: systematic review and meta-
analysis. Clin Implant Dent Relat Res. 20(2):251–260.
Dickersin K. 1990. The existence of publication bias and risk factors for its 
occurrence. JAMA. 263(10):1385–1389.
Fanelli D. 2012. Negative results are disappearing from most disciplines and 
countries. Scientometrics. 90(3):891–904.
Gehr BT, Weiss C, Porzsolt F. 2006. The fading of reported effectiveness: a meta-
analysis of randomised controlled trials. BMC Med Res Methodol. 6:25.
Ioannidis JP. 2005. Contradicted and initially stronger effects in highly cited 
clinical research. JAMA. 294(2):218–228.
Ioannidis JP. 2008. Why most discovered true associations are inflated. 
Epidemiology. 19(5):640–648.
Li R, Liu Y, Xu T, Zhao H, Hou J, Wu Y, Zhang D. 2019. The additional 
effect of autologous platelet concentrates to coronally advanced flap in the 
treatment of gingival recessions: a systematic review and meta-analysis. 
Biomed Res Int. 2019:2587245.
Luo Y, Chaimani A, Furukawa TA, Kataoka Y, Ogawa Y, Cipriani A, Salanti 
G. 2021. Visualizing the evolution of evidence: cumulative network meta-
analyses of new generation antidepressants in the last 40 years. Res Synth 
Methods. 12(1):74–85.
Open Science Collaboration. 2015. Estimating the reproducibility of psycho-
logical science. Science. 349(6251):aac4716.
Panda S, Karanxha L, Goker F, Satpathy A, Taschieri S, Francetti L, Das AC, 
Kumar M, Panda S, Fabbro MD. 2019. Autologous platelet concentrates in 
treatment of furcation defects—a systematic review and meta-analysis. Int 
J Mol Sci. 20(6):1347.
Persaud N, Heneghan C. 2021. Novelty bias. In: Catalog of bias [accessed 2021 
Feb 15]. https://catalogofbias.org/biases/novelty-bias/
Riley RD, Higgins JP, Deeks JJ. 2011. Interpretation of random effects meta-
analyses. BMJ. 342:d549.
Salanti G, Dias S, Welton NJ, Ades AE, Golfinopoulos V, Kyrgiou M, Mauri 
D, Ioannidis JP. 2010. Evaluating novel agent effects in multiple-treatments 
meta-regression. Stat Med. 29(23):2369–2383.
Savović J, Jones H, Altman D, Harris R, Jűni P, Pildal J, Als-Nielsen B, Balk 
E, Gluud C, Gluud L, et al. 2012. Influence of reported study design char-
acteristics on intervention effect estimates from randomised controlled tri-
als: combined analysis of meta-epidemiological studies. Health Technol 
Assess. 16(35):1–82.
Savovic J, Turner RM, Mawdsley D, Jones HE, Beynon R, Higgins JPT, Sterne 
JAC. 2018. Association between risk-of-bias assessments and results of 
randomized trials in Cochrane reviews: the ROBES meta-epidemiologic 
study. Am J Epidemiol. 187(5):1113–1122.
Schulz KF, Chalmers I, Hayes RJ, Altman DG. 1995. Empirical evidence of 
bias: dimensions of methodological quality associated with estimates of 
treatment effects in controlled trials. JAMA. 273(5):408–412.
Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, Moher D, Tugwell 
P, Welch V, Kristjansson E, et al. 2017. AMSTAR 2: a critical appraisal 
tool for systematic reviews that include randomised or non-randomised 
studies of healthcare interventions, or both. BMJ. 358:j4008.
Simmons JP, Nelson LD, Simonsohn U. 2011. False-positive psychology: 
undisclosed flexibility in data collection and analysis allows presenting 
anything as significant. Psychol Sci. 22(11):1359–1366.
Tinè F, Attanasio M, Muggeo VMR, Crainiceanu CM. 2017. Evidence of bias 
in randomized clinical trials of hepatitis C interferon therapies. Clin Trials. 
14(5):483–488.
Tu YK, Tugnait A, Clerehugh V. 2008. Is there a temporal trend in the 
reported treatment efficacy of periodontal regeneration? A meta-analysis of 
randomized-controlled trials. J Clin Periodontol. 35(2):139–146.
